BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelDaniele Perna, David J. Adams, Mamunur Rashid et al.|Proceedings of the National Academy of Sciences|2015Cited by 143
Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumoursHi̇lal Özdağ, Carlos Caldas, Sarah J. Batley et al.|British Journal of Cancer|2002Cited by 61
RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancerSarah Taylor, Mark J. Arends|Frontiers in Oncology|2024Cited by 3